SNDX beat EPS expectations by 27.80%
May 05, 2025, 10:36 PM
0.00%
What does SNDX do
Syndax Pharmaceuticals, based in Waltham, Massachusetts, develops cancer therapies and went public on March 3, 2016. Key products include revumenib for leukemia and axatilimab for chronic graft-versus-host disease.
Syndax Pharmaceuticals (SNDX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Syndax Pharmaceuticals's actual EPS was -$0.98, beating the estimate of -$1.36 per share, resulting in a 27.80% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.